Acrux Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Acrux ha un patrimonio netto totale di A$3.3M e un debito totale di A$1.5M, che porta il suo rapporto debito/patrimonio netto a 45.4%. Le sue attività totali e le sue passività totali sono rispettivamente A$9.0M e A$5.7M.

Informazioni chiave

45.4%

Rapporto debito/patrimonio netto

AU$1.49m

Debito

Indice di copertura degli interessi	n/a
Contanti	AU$2.95m
Patrimonio netto	AU$3.28m
Totale passività	AU$5.69m
Totale attività	AU$8.96m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Nov 16

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

Nov 16

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Sep 21

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

May 20

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Feb 04

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Dec 14

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( A$6.0M ) di ACR superano le sue passività a breve termine ( A$3.7M ).

Passività a lungo termine: Le attività a breve termine di ACR ( A$6.0M ) superano le sue passività a lungo termine ( A$2.0M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: ACR ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di ACR è aumentato da 0% a 45.4% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: ACR ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: ACR ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a crescere ai tassi storici del 17 % ogni anno.

Acrux Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Recent updates

New major risk - Market cap size

Acrux Limited, Annual General Meeting, Nov 21, 2024

New major risk - Financial position

Full year 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

First half 2024 earnings released: AU$0.011 loss per share (vs AU$0.011 loss in 1H 2023)

Acrux Limited to Report First Half, 2024 Results on Feb 23, 2024

Acrux Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.035 loss in FY 2022)

New minor risk - Financial data availability

New minor risk - Share price stability

Independent Non-Executive Director recently bought AU$92k worth of stock

First half 2023 earnings released: AU$0.011 loss per share (vs AU$0.019 loss in 1H 2022)

Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Acrux Limited, Annual General Meeting, Nov 23, 2022

Full year 2022 earnings released: AU$0.035 loss per share (vs AU$0.057 loss in FY 2021)

Acrux's Sixth Generic Dossier Accepted by FDA for Review

Less than half of directors are independent

Non-Executive Director recently bought AU$89k worth of stock

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Acrux Limited Announces Fifth Generic Dossier Accepted by FDA for Review

Acrux Limited Launches Testosterone Topical Solution USP, 30mg Per Actuation

Full year 2021 earnings released: AU$0.057 loss per share (vs AU$0.056 loss in FY 2020)

CFO & Company Secretary Deborah Ambrosini has left the company

Acrux Receives Approval from the FDA for Its Generic Version of Jublia

Non Executive Director Norman Gray has left the company

Acrux Confirms Patent Challenge

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Acrux Limited Announces the US Food and Drug Administration Approves its Generic Product Based on Perrigo's Testosterone Topical Solution, 30mg/1.5mL

New 90-day high: AU$0.21

Acrux Limited announced that it expects to receive AUD 7.815143 million in funding from Bioscience Managers Pty Ltd and other investors

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Acrux Limited Signs Licensing Agreement with Dash Pharmaceuticals

Full year earnings released - AU$0.057 loss per share

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane